Gelonghui, December 5 | According to Nikkei Chinese, Oasis Management, a Hong Kong investment fund holding over 7% of Kobayashi Pharmaceutical's equity, recently demanded Kobayashi Pharmaceutical to sue seven individuals including the former chairman of the group for over 10 billion yen in damages. They also warned that if the supervisors of Kobayashi Pharmaceutical do not take action on behalf of the company, Oasis could file a shareholder representative lawsuit by the end of January next year. According to information, the expenses related to the red yeast problem incurred by Kobayashi Pharmaceutical from January to September this year were included in the special losses of over 10 billion yen. According to numerous shareholding reports, after increasing their shareholding in Kobayashi Pharmaceutical, Oasis holds a 7.54% stake, making it the fourth largest shareholder, following the largest shareholder, former president Kobayashi and others, based on the shareholder composition as of the end of June. The report pointed out that Oasis's targets for compensation include Kobayashi Kazumasa, a special advisor and former chairman from the Kobayashi Pharmaceutical founding family; former president Kobayashi Akihiro; current president Yamakane Satoshi; as well as four independent directors, including Kunio Ito, an honorary professor at Hitotsubashi University, and Kaori Sasaki, president of Ewoman, covering all directors at the time the issue was exposed.